{{Rsnum
|rsid=11067600
|Chromosome=12
|position=115439972
|Orientation=plus
|GMAF=0.1983
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 24.1 | 46.7 | 29.2
| JPT | 23.0 | 55.8 | 21.2
| YRI | 6.8 | 33.6 | 59.6
| ASW | 5.3 | 28.1 | 66.7
| CHB | 24.1 | 46.7 | 29.2
| CHD | 23.9 | 49.5 | 26.6
| GIH | 3.0 | 31.7 | 65.3
| LWK | 5.5 | 26.4 | 68.2
| MEX | 3.4 | 34.5 | 62.1
| MKK | 1.3 | 11.5 | 87.2
| TSI | 0.0 | 3.0 | 97.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11067600
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.07, combined P value= 5.56E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470175
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11067600
|overall_frequency_n=24
|overall_frequency_d=128
|overall_frequency=0.1875
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=23
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=3
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}